Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 5
2004 5
2005 5
2006 7
2007 2
2008 1
2009 5
2010 5
2011 4
2012 2
2013 4
2014 5
2015 3
2016 2
2017 1
2018 1
2019 7
2020 4
2021 3
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

73 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean de jonge mj (120 results)?
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lönnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skyttä T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmén M. Virtakoivu R, et al. Among authors: de jonge mja. Clin Cancer Res. 2021 Aug 1;27(15):4205-4220. doi: 10.1158/1078-0432.CCR-20-4862. Epub 2021 Jun 2. Clin Cancer Res. 2021. PMID: 34078651 Clinical Trial.
Aurora kinase inhibitors.
Kitzen JJ, de Jonge MJ, Verweij J. Kitzen JJ, et al. Crit Rev Oncol Hematol. 2010 Feb;73(2):99-110. doi: 10.1016/j.critrevonc.2009.03.009. Epub 2009 Apr 14. Crit Rev Oncol Hematol. 2010. PMID: 19369091 Review.
Renal toxicities of chemotherapy.
de Jonge MJ, Verweij J. de Jonge MJ, et al. Semin Oncol. 2006 Feb;33(1):68-73. doi: 10.1053/j.seminoncol.2005.11.011. Semin Oncol. 2006. PMID: 16473645 Review.
Role of pharmacogenetics in irinotecan therapy.
de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH. de Jong FA, et al. Cancer Lett. 2006 Mar 8;234(1):90-106. doi: 10.1016/j.canlet.2005.04.040. Epub 2005 Dec 15. Cancer Lett. 2006. PMID: 16343744 Review.
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz-Padilla I, Schellens JHM. van Bussel MTJ, et al. Among authors: de jonge mja. Br J Cancer. 2021 Feb;124(4):728-735. doi: 10.1038/s41416-020-01151-6. Epub 2020 Nov 24. Br J Cancer. 2021. PMID: 33230210 Free PMC article. Clinical Trial.
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM. van der Noll R, et al. Among authors: de jonge mja. Invest New Drugs. 2020 Aug;38(4):1117-1128. doi: 10.1007/s10637-019-00856-7. Epub 2019 Oct 30. Invest New Drugs. 2020. PMID: 31667659 Clinical Trial.
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. van der Velden DL, et al. Among authors: de jonge mja. Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30. Nature. 2019. PMID: 31570881 Clinical Trial.
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, de Bono JS, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM. van der Noll R, et al. Among authors: de jonge mja. Invest New Drugs. 2020 Aug;38(4):1096-1107. doi: 10.1007/s10637-019-00857-6. Epub 2019 Oct 21. Invest New Drugs. 2020. PMID: 31637669 Clinical Trial.
73 results